Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
There was no significant association between higher intake of rice and elevated risk of developing type 2 diabetes (T2D) in Asians, according to the Singapore Chinese Health Study.
Weight gain over the Christmas holiday period can be prevented through a brief behavioural intervention involving regular self-weighing, weight management advice and information about the amount of physical activity needed to expend the calories in foods and drinks, suggests a study.
It appears that biguanides and statins have inhibitory effect on neuroendocrine tumour (NET)-cell aggressiveness, a recent study has shown.
With the exception of dipeptidyl peptidase 4 inhibitors (DPP4i), other drugs used for managing diabetes do not correlate with an elevated risk of bullous pemphigoid (BP) in a Finnish patient database, reports a recent study. This indicates that the investigated drugs can be used safely in the said population.
A rotating night shift work and an unhealthy lifestyle can both lead to a higher risk of type 2 diabetes (T2D) among female nurses, according to a recent study. The joint effect is greater than the addition of the risks associated with a higher risk of T2D.
Patients with simple obesity may fare well with metformin, which yields reductions in body weight without inducing hypoglycaemia as a side effect, a recent study reports.
Sonographic patterns outlined by three guidelines (the 2015 American Thyroid Association [ATA] Management Guidelines, the 2014 British Thyroid Association [BTA] Guidelines for the Management of Thyroid Cancer and the Thyroid Imaging Reporting and Data System TIRADS]) have high sensitivity and negative predictive value (NPV), which are needed for triaging of thyroid nodules for subsequent fine needle aspiration (FNA), according to a Singapore study.
Special Reports
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
At the AstraZeneca-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congress at Hilton Kuala Lumpur, Professor Ronald Ma highlighted the role of a novel combination therapy in reducing HbA1c levels while simultaneously providing cardiovascular (CV) protection to improve patient outcomes.
The FOURIER trial previously demonstrated that adding the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor evolocumab to background statin therapy lowered LDL-cholesterol (LDL-C) below target levels and significantly reduced the risks of cardiovascular (CV) events in patients with atherosclerotic cardiovascular disease (ASCVD). At the European Society of Cardiology (ESC) Congress 2018 in Munich, Germany, experts reiterated how evolocumab helps lower LDL-C levels and reduces CV events even in patients with various comorbidities.
At the recent ‘Reinforced for the Glycaemic Challenge’ symposium held at Shangri-la Hotel, Kuala Lumpur, Associate Professor Dr Alexander Tan, Professor Dr Chee Kok Han and Dr Chan Siew Pheng shared their insights into the importance of achieving glycaemic control in patients with type 2 diabetes mellitus (T2DM), while simultaneously providing them with cardiovascular protection.
At a recent lunch symposium held in conjunction with the 1st Malaysian Advances in Women’s Health Congress 2016, Professor Dr Jamiyah Hassan imparted clinical updates and strategies for the optimization of hormone replacement therapy in menopausal women. Highlights from her presentation are summarized below.
At the recent Malaysian Osteoporosis Society 2016 Clinical Practice Guideline (CPG) Meeting held on the 8th of October 2016 at Ibis Styles Ipoh, Dr Hew Fen Lee and Professor Dr Chan Siew Pheng presented clinical guidance on the management of osteoporosis, and discussed whether the benefits of treatment outweigh the risks.
At the Diabetes Asia 2016 Conference organized by the National Diabetes Institute, Professor Jean Claude Mbanya presented the case for why gliclazide modified release (MR; Diamicron® MR, Servier) should be the treatment of choice for early and aggressive control of type 2 diabetes (T2D).
Conference Reports
In what many clinicians believed was a rare breakthrough, the prescription fish oil icosapent ethyl cut the risk of ischaemic events among statin-treated patients with high triglyceride levels and either cardiovascular disease (CVD) or diabetes in the REDUCE-IT* trial, putting fish oil on the front burner.
The Ministry of Health (MOH), Malaysia continues to strive towards achieving the optimal glycaemic target and reducing the impact of diabetes complications among patients.
Higher ideal levels of dietary intake, physical activity, smoking, blood pressure (BP), cholesterol and body mass index (BMI) are associated with a dose-dependent lower risk of type 2 diabetes (T2D) for individuals with normal fasting glucose but not impaired fasting glucose, according to a study presented at the American Heart Association (AHA) Scientific Sessions 2018.
Slideshow: Highlights from the American Heart Association (AHA) Scientific Sessions 2018
Treatment with the SGLT2i* empagliflozin appears to significantly reduce left ventricular mass (LVM) among patients with type 2 diabetes (T2D), according to results of the EMPA-HEART** CardioLink-6 trial presented at AHA 2018.
Coronary revascularization with bypass surgery proves to be superior to drug eluting stents in the long term in preventing all-cause mortality in patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), even 8 years after the procedure, the FREEDOM* Follow-On Study reveals.
Dapagliflozin reduced the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) who had established or multiple risk factors for atherosclerotic cardiovascular disease (CVD), according to results of the DECLARE-TIMI 58* trial presented at AHA 2018. However, it did not reduce the incidence of major adverse cardiovascular events (MACE)**.
Multimedia
